Tratamento da Dermite Atópica Moderada a Grave em Adultos

Pedro Ponte

Resumo


A dermite atópica é uma doença cutânea inflamatória crónica, caracterizada por lesões eritemato-descamativas pruriginosas recorrentes, frequentemente associadas a sobreinfecção. É uma das mais comuns doenças cutâneas, afectando 10% a 20% das crianças e 1% a 3% dos adultos, sendo uma causa significativa de morbilidade, compromisso de qualidade de vida e consumo de cuidados de saúde. Ainda que muitos doentes possam ser tratados de forma satisfatória com medicação tópica e fototerapia, um subgrupo de doentes requer terapêutica sistémica mais agressiva para controlar a inflamação cutânea, reduzir sintomas, prevenir exacerbações e melhorar a qualidade de vida. Para além disso, as formas graves da doença têm um profundo impacto na vida dos doentes o que requer a combinação de tratamentos tópicos e sistémicos para as controlar, depois de adequadamente excluídos os motivos para falência terapêutica. Apesar das múltiplas opções clássicas disponíveis, terapêuticas eficazes e seguras estão limitadas pela toxicidade cumulativa e efeitos adversos associados. Este artigo revê o uso e a evidência científica disponível destas opções de tratamento na dermite atópica moderada a grave do adulto, bem como vários novos e promissores fármacos presentemente em investigação.


Palavras-chave


Adulto; Anticorpos Monoclonais; Dermatite Atópica/tratamento; Eczema; Fototerapia

Texto Completo:

PDF

Referências


Williams HC. Epidemiology of atopic dermatitis. Clin

Exp Dermatol. 2000;25:522-9. doi:10.1046/j.1365-

2000.00698.x.

Hanifin JM, Reed ML. A population-based survey of

eczema prevalence in the United States. Dermat Contact

Atopic Occup Drug. 2007;18:82-91.

Carroll CL, Balkrishnan R, Feldman SR, Fleischer

ABJ, Manuel JC. The burden of atopic

dermatitis: impact on the patient, family, and society. Pediatr

Dermatol. 2005;22:192-9. doi:10.1111/j.1525-

2005.22303.x.

Kemp AS. Cost of illness of atopic dermatitis in children:

a societal perspective. Pharmacoeconomics.

;21:105-113.

Lapidus CS, Kerr PE. Social impact of atopic dermatitis.

Med Health R I. 2001;84:294-5.

Chamlin SL, Frieden IJ, Williams ML, Chren M-M.

Effects of atopic dermatitis on young American children

and their families. Pediatrics. 2004;114:607-11.

doi:10.1542/peds.2004-0374.

Fivenson D, Arnold RJG, Kaniecki DJ, Cohen JL, Frech F,

Finlay AY. The effect of atopic dermatitis on total burden

of illness and quality of life on adults and children in a

large managed care organization. J Manag Care Pharm.

;8:333-42. doi:10.18553/jmcp.2002.8.5.333.

Finlay AY, Khan GK. Dermatology Life Quality Index

(DLQI)-a simple practical measure for routine clinical

use. Clin Exp Dermatol. 1994;19:210-6.

Kiebert G, Sorensen S V, Revicki D, et al. Atopic dermatitis

is associated with a decrement in health-related quality

of life. Int J Dermatol. 2002;41:151-8.

Weidinger S, Novak N. Atopic dermatitis. Lancet.

;387:1109-122. doi:10.1016/S0140-

-6736(15)00149-X.

Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb

A. Clinical validation and guidelines for the SCORAD

index: consensus report of the European Task Force on

Atopic Dermatitis. Dermatology. 1997;195:10-9.

Schmitt J, Langan S, Deckert S, et al. Assessment of

clinical signs of atopic dermatitis: a systematic review

and recommendation. J Allergy Clin Immunol.

;132:1337-47. doi:10.1016/j.jaci.2013.07.008.

Chopra R, Silverberg JI. Assessing the severity of atopic

dermatitis in clinical trials and practice. Clin

Dermatol. 2018;36:606-15. doi:10.1016/j.clindermatol.

05.012.

Arkwright PD, Motala C, Subramanian H, Spergel J,

Schneider LC, Wollenberg A. Management of difficult-

-to-treat atopic dermatitis. J Allergy Clin Immunol Pract.

;1:142-51. doi:10.1016/j.jaip.2012.09.002.

Ring J, Alomar A, Bieber T, et al. Guidelines for treatment

of atopic eczema (atopic dermatitis) Part I. J

Eur Acad Dermatology Venereol. 2012;26:1045-60.

doi:10.1111/j.1468-3083.2012.04635.x.

Ring J, Alomar A, Bieber T, et al. Guidelines for treatment

of atopic eczema (atopic dermatitis) Part II. J

Eur Acad Dermatology Venereol. 2012;26:1176-93.

doi:10.1111/j.1468-3083.2012.04636.x.

Baumer JH. Atopic eczema in children, NICE. Arch

Dis Child Educ Pract Ed. 2008;93:93-7. doi:10.1136/

adc.2008.139626.

Silverberg NB. A practical overview of pediatric atopic

dermatitis, part 2: triggers and grading. Cutis.

;97:326-9.

Kiken DA, Silverberg NB. Atopic dermatitis in children,

part 1: epidemiology, clinical features, and complications.

Cutis. 2006;78:241-7.

Breuer K, HAussler S, Kapp A, Werfel T. Staphylococcus

aureus: colonizing features and influence of an antibacterial

treatment in adults with atopic dermatitis. Br J

Dermatol. 2002;147:55-61.

Bjerre RD, Bandier J, Skov L, Engstrand L, Johansen JD.

The role of the skin microbiome in atopic dermatitis: a

systematic review. Br J Dermatol. 2017;177:1272-8.

doi:10.1111/bjd.15390.

Adachi J, Endo K, Fukuzumi T, Tanigawa N, Aoki T. Increasing

incidence of streptococcal impetigo in atopic

dermatitis. J Dermatol Sci. 1998;17:45-53.

Wollenberg A, Zoch C, Wetzel S, Plewig G, Przybilla

B. Predisposing factors and clinical features of eczema

herpeticum: a retrospective analysis of 100 cases. J Am

Acad Dermatol. 2003;49:198-205.

Roul S, Ducombs G, Taieb A. Usefulness of the European

standard series for patch testing in children. A 3-year

single-centre study of 337 patients. Contact Dermatitis.

;40:232-5.

Brasch J, Geier J. Patch test results in schoolchildren.

Results from the Information Network of Departments

of Dermatology (IVDK) and the German Contact Dermatitis

Research Group (DKG). Contact Dermatitis.

;37:286-93.

Tada J, Toi Y, Arata J. Atopic dermatitis with severe facial

lesions exacerbated by contact dermatitis from topical

medicaments. Contact Dermatitis. 1994;31:261-3.

Giordano-Labadie F, Rance F, Pellegrin F, Bazex J, Dutau

G, Schwarze HP. Frequency of contact allergy in children

with atopic dermatitis: results of a prospective study of

cases. Contact Dermatitis. 1999;40:192-5.

Mailhol C, Lauwers-Cances V, Rancé F, Paul C, Giordano-

Labadie F. Prevalence and risk factors for allergic

contact dermatitis to topical treatment in atopic dermatitis:

a study in 641 children. Allergy. 2009;64:801-6.

doi:10.1111/j.1398-9995.2008.01890.x.

Eichenfield LF, Hanifin JM, Beck LA, et al. Atopic dermatitis

and asthma: parallels in the evolution of treatment.

Pediatrics. 2003;111:608-16.

Naldi L, Parazzini F, Gallus S. Prevalence of atopic

dermatitis in Italian schoolchildren: factors affecting

its variation. Acta Derm Venereol. 2009;89):122-5.

doi:10.2340/00015555-0591.

Schafer T. The impact of allergy on atopic eczema

from data from epidemiological studies. Curr Opin

Allergy Clin Immunol. 2008;8:418-22. doi:10.1097/

ACI.0b013e32830e71a7.

Flohr C, Johansson SGO, Wahlgren C-F, Williams H.

How atopic is atopic dermatitis? J Allergy Clin Immunol.

;114:150-8. doi:10.1016/j.jaci.2004.04.027.

Breuer K, Heratizadeh A, Wulf A, et al. Late eczematous

reactions to food in children with atopic dermatitis. Clin

Exp Allergy. 2004;34:817-24. doi:10.1111/j.1365-

2004.1953.x.

Boyce JA, Assa’ad A, Burks AW, et al. Guidelines for the

diagnosis and management of food allergy in the United

States: report of the NIAID-sponsored expert panel.

J Allergy Clin Immunol. 2010;126(6 Suppl):S1-58.

doi:10.1016/j.jaci.2010.10.007.

Bath-Hextall F, Delamere FM, Williams HC. Dietary exclusions

for established atopic eczema. Cochrane Database

Syst Rev. 2008;1:CD005203. doi:10.1002/14651858.

CD005203.pub2.

Tupker RA, De Monchy JG, Coenraads PJ, Homan

A, van der Meer JB. Induction of atopic dermatitis by

inhalation of house dust mite. J Allergy Clin Immunol.

;97:1064-70.

Nankervis H, Pynn E V, Boyle RJ, Rushton L, Williams

HC, Hewson DM, et al. House dust mite reduction

and avoidance measures for treating eczema.

Cochrane Database Syst Rev. 2015;1:CD008426.

doi:10.1002/14651858.CD008426.pub2.

Krejci-Manwaring J, Tusa MG, Carroll C, Camacho

F, Kaur M, Carr D, et al. Stealth monitoring of adherence

to topical medication: Adherence is very poor in

children with atopic dermatitis. J Am Acad Dermatol.

;56:211-6. doi:10.1016/j.jaad.2006.05.073.

Ohya Y, Williams H, Steptoe A, Saito H, Iikura Y, Anderson

R, et al. Psychosocial factors and adherence to

treatment advice in childhood atopic dermatitis. J Invest

Dermatol. 2001;117):852-7. doi:10.1046/j.0022-

x.2001.01475.x.

Misery L, Ortonne J-P, Cambazard F, Guillet G, Thomas

L, Lorette G, et al. PPAD: a tool for presumption of atopic

dermatitis. J Dermatol. 2012;39:151-5. doi:10.1111/

j.1346-8138.2011.01381.x.

Hanifin J. Diagnostic features of atopic dermatitis. Acta

Dermatovener. 1980;92:44-7.

Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ,

Hunter JJ, et al. The U.K. Working Party’s Diagnostic Criteria

for Atopic Dermatitis. I. Derivation of a minimum

set of discriminators for atopic dermatitis. Br J Dermatol.

;131:383-96.

Eichenfield LF, Hanifin JM, Luger TA, Stevens SR, Pride

HB. Consensus conference on pediatric atopic dermatitis.

J Am Acad Dermatol. 2003;49:1088-95. doi:10.1067/

S0190.

Meduri NB, Vandergriff T, Rasmussen H, Jacobe

H. Phototherapy in the management of

atopic dermatitis: a systematic review. Photodermatol Photoimmunol

Photomed. 2007;23:106-12. doi:10.1111/

j.1600-0781.2007.00291.x.

Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger

TG, Bergman JN, et al. Guidelines of care for the management

of atopic dermatitis: Section 3. Management

and treatment with phototherapy and systemic agents.

J Am Acad Dermatol. 2014;71:327-49. doi:10.1016/j.

jaad.2014.03.030.

Reynolds NJ, Franklin V, Gray JC, Diffey BL, Farr PM.

Narrow-band ultraviolet B and broad-band ultraviolet A

phototherapy in adult atopic eczema: a randomised controlled

trial. Lancet. 2001;357:2012-6. doi:10.1016/

S0140-6736(00)05114-X.

Fernandez-Guarino M, Aboin-Gonzalez S, Barchino

L, Velazquez D, Arsuaga C, Lazaro P. Treatment of

moderate and severe adult chronic atopic dermatitis with

narrow-band UVB and the combination of narrow-band

UVB/UVA phototherapy. Dermatol Ther. 2016;29:19-

doi:10.1111/dth.12273.

Hjerppe M, Hasan T, Saksala I, Reunala T. Narrow-band

UVB treatment in atopic dermatitis. Acta Derm Venereol.

;81:439-40.

Dayal S, Pathak K, Sahu P, Jain VK. Narrowband UV-B

phototherapy in childhood atopic dermatitis: efficacy

and safety. An Bras Dermatol. 2017;92:801-6.

doi:10.1590/abd1806-4841.20175958.

Majoie IML, Oldhoff JM, van Weelden H, Laaper-Ertmann

M, Bousema MT, Sigurdsson V, et al. Narrowband

ultraviolet B and medium-dose ultraviolet A1 are

equally effective in the treatment of moderate to severe

atopic dermatitis. J Am Acad Dermatol. 2009;60:77-84.

doi:10.1016/j.jaad.2008.08.048.

Gambichler T, Othlinghaus N, Tomi NS, Holland-

-Letz T, Boms S, Skrygan M,et al. Medium-dose ultraviolet

(UV) A1 vs. narrowband UVB phototherapy

in atopic eczema: a randomized crossover study. Br J

Dermatol. 2009;160:652-8. doi:10.1111/j.1365-

2008.08984.x.

Garritsen FM, Brouwer MW, Limpens J, Spuls PI.

Photo(chemo)therapy in the management of atopic dermatitis:

an updated systematic review with implications

for practice and research. Br J Dermatol. 2014;170:501-

doi:10.1111/bjd.12645.

Tzaneva S, Kittler H, Holzer G, Reljic D, Weber M, Hönigsmann

H, et al. 5-Methoxypsoralen plus ultraviolet (UV)

A is superior to medium-dose UVA1 in the treatment of

severe atopic dermatitis: a randomized crossover trial.

Br J Dermatol. 2010;162:655-60. doi:10.1111/j.1365-

2009.09514.x.

Der-Petrossian M, Seeber A, Honigsmann H, Tanew A.

Half-side comparison study on the efficacy of 8-methoxypsoralen

bath-PUVA versus narrow-band ultraviolet B

phototherapy in patients with severe chronic atopic dermatitis.

Br J Dermatol. 2000;142:39-43.

Stern RS. The risk of melanoma in association with

long-term exposure to PUVA. J Am Acad Dermatol.

;44:755-61. doi:10.1067/mjd.2001.114576.

Nijsten TEC, Stern RS. The increased risk of skin cancer

is persistent after discontinuation of psoralen+ultraviolet

A: a cohort study. J Invest Dermatol. 2003;121:252-8.

doi:10.1046/j.1523-1747.2003.12350.x.

Patel R V, Clark LN, Lebwohl M, Weinberg JM. Treatments

for psoriasis and the risk of malignancy. J Am

Acad Dermatol. 2009;60:1001-17. doi:10.1016/j.

jaad.2008.12.031.

Gambichler T. Management of atopic dermatitis using

photo(chemo)therapy. Arch Dermatol Res. 2009;301:197-

doi:10.1007/s00403-008-0923-5.

Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS,

Schwarzenberger K, et al. Guidelines of care for the management

of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.

J Am Acad Dermatol. 2014;71:116-32. doi:10.1016/j.

jaad.2014.03.023.

Devillers AC, Oranje AP. Wet-wrap treatment in children

with atopic dermatitis: a practical guideline.

Pediatr Dermatol. 2012;29:24-7. doi:10.1111/j.1525-

2011.01691.x.

Oranje AP, Devillers ACA, Kunz B, Jones SL, DeRaeve

L, Van Gysel D, et al. Treatment of patients with

atopic dermatitis using wet-wrap dressings with diluted

steroids and/or emollients. An expert panel’s

opinion and review of the literature. J Eur Acad Dermatol

Venereol. 2006;20:1277-6. doi:10.1111/j.1468-

2006.01790.x.

Devillers ACA, de Waard-van der Spek FB, Mulder

PG, Oranje AP. Treatment of refractory atopic dermatitis

using “wet-wrap” dressings and diluted corticosteroids:

results of standardized treatment in both

children and adults. Dermatology. 2002;204:50-5.

doi:10.1159/000051810.

Foelster-Holst R, Nagel F, Zoellner P, Spaeth D. Efficacy

of crisis intervention treatment with topical corticosteroid

prednicarbat with and without partial wet-wrap dressing

in atopic dermatitis. Dermatology. 2006;212:66-9.

doi:10.1159/000089025.

Xu W, Li Y, Chen Z, Liu T, Wang S, Li L. Wet-wrap therapy

with halometasone cream for severe adult atopic dermatitis.

Postgrad Med. 2018 (in press). doi:10.1080/00

2018.1478108.

Gonzalez-Lopez G, Ceballos-Rodriguez RM, Gonzalez-

-Lopez JJ, Feito Rodriguez M, Herranz-Pinto P. Efficacy

and safety of wet wrap therapy for patients with atopic

dermatitis: a systematic review and meta-analysis. Br J

Dermatol. 2017;177:688-95. doi:10.1111/bjd.15165.

Amor KT, Ryan C, Menter A. The use of cyclosporine in

dermatology: part I. J Am Acad Dermatol. 2010;63:925-

doi:10.1016/j.jaad.2010.02.063.

Schmitt J, Schmitt N, Meurer M. Cyclosporin in the

treatment of patients with atopic eczema - a systematic

review and meta-analysis. J Eur Acad

Dermatol Venereol. 2007;21:606-19. doi:10.1111/

j.1468-3083.2006.02023.x.

Harper JI, Berth-Jones J, Camp RD, Dillon MJ, Finlay

AY, Holden CA, et al. Cyclosporin for atopic dermatitis

in children. Dermatology. 2001;203:3-6.

doi:10.1159/000051694.

Brazzelli V, Prestinari F, Chiesa MG, Borroni RG, Ardigo

M, Borroni G. Sequential treatment of severe atopic dermatitis

with cyclosporin A and low-dose narrow-band

UVB phototherapy. Dermatology. 2002;204:252-4.

doi:10.1159/000057893.

Zonneveld IM, De Rie MA, Beljaards RC, Van Der Rhee

HJ, Wuite J, Zeegelaar J, et al. The long-term safety and

efficacy of cyclosporin in severe refractory atopic dermatitis:

a comparison of two dosage regimens. Br J Dermatol.

;135 Suppl:15-20.

Berth-Jones J, Graham-Brown RA, Marks R, Camp RD,

English JS, Freeman K, et al. Long-term efficacy and safety

of cyclosporin in severe adult atopic dermatitis. Br J

Dermatol. 1997;136:76-81.

Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P,

Cork MJ, et al. Cyclosporin for severe childhood atopic

dermatitis: short course versus continuous therapy. Br J

Dermatol. 2000;142:52-8.

Haeck IM, Knol MJ, Ten Berge O, van Velsen SGA, de

Bruin-Weller MS, Bruijnzeel-Koomen CAFM. Enteric-

-coated mycophenolate sodium versus cyclosporin A

as long-term treatment in adult patients with severe

atopic dermatitis: a randomized controlled trial. J Am

Acad Dermatol. 2011;64:1074-84. doi:10.1016/j.

jaad.2010.04.027.

Granlund H, Erkko P, Remitz A, Langeland T, Helsing P,

Nuutinen M,et al. Comparison of cyclosporin and UVAB

phototherapy for intermittent one-year treatment of atopic

dermatitis. Acta Derm Venereol. 2001;81:22-7.

Kim C-H, Cheong KA, Park CD, Lee A-Y. Glucosamine

improved atopic dermatitis-like skin lesions in NC/

Nga mice by inhibition of Th2 cell development. Scand

J Immunol. 2011;73:536-45. doi:10.1111/j.1365-

2011.02526.x.

Kwon H-B, Ahn B-J, Choi Y, Jin SY, Cheong KA, Lee J, et

al. Combination of glucosamine improved therapeutic

effect of low-dose cyclosporin A in patients with atopic

dermatitis: a pilot study. J Dermatol. 2013;40:207-10.

doi:10.1111/1346-8138.12003.

Jin S-Y, Lim W-S, Sung NH, Cheong KA, Lee A-Y. Combination

of glucosamine and low-dose cyclosporine for

atopic dermatitis treatment: a randomized, placebo-

-controlled, double-blind, parallel clinical trial. Dermatol

Ther. 2015;28:44-51. doi:10.1111/dth.12163.

Goujon C, Viguier M, Staumont-Salle D, Bernier C, Guillet

G, Lahfa M, et al. Methotrexate versus cyclosporine

in adults with moderate-to-severe atopic dermatitis: a

phase III randomized noninferiority trial. J allergy Clin

Immunol Pract. 2018; 6:562-9.e3. doi:10.1016/j.

jaip.2017.07.007.

Law Ping Man S, Bouzille G, Beneton N, Safa G, Dupuy

A, Droitcourt C. Drug survival and postdrug survival of

first-line immunosuppressive treatments for atopic dermatitis:

comparison between methotrexate and cyclosporine.

J Eur Acad Dermatol Venereol. 2018 (in press).

doi:10.1111/jdv.14880.

Flohr C, Irvine AD. Systemic therapies for severe atopic

dermatitis in children and adults. J Allergy Clin Immunol.

;132:774-4.e6. doi:10.1016/j.jaci.2013.03.016.

Holme SA, Duley JA, Sanderson J, Routledge PA, Anstey

AV. Erythrocyte thiopurine methyl transferase assessment

prior to azathioprine use in the UK. QJM. 2002;95:439-

Schram ME, Borgonjen RJ, Bik CMJM, van der Schroeff

JG, van Everdingen JJE, Spuls PI. Off-label use of

azathioprine in dermatology: a systematic review. Arch Dermatol. 2011;147:474-88. doi:10.1001/archdermatol.

79.

Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S,

Ahmed I, et al. Azathioprine in severe adult atopic dermatitis:

a double-blind, placebo-controlled, crossover

trial. Br J Dermatol. 2002;147:324-30.

Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by

thiopurine methyltransferase activity for moderate-to-severe

atopic eczema: a double-blind, randomised controlled

trial. Lancet. 2006;367:839-46. doi:10.1016/

S0140-6736(06)68340-2.

Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt

J, Spuls PI. A randomized trial of methotrexate

versus azathioprine for severe atopic eczema. J

Allergy Clin Immunol. 2011;128:353-9. doi:10.1016/j.

jaci.2011.03.024.

Gerbens LA, Hamann SA, Brouwer MW, Roekevisch E,

Leeflang MM, Spuls PI. Methotrexate and azathioprine

in severe atopic dermatitis: a 5-year follow up study

of a randomised controlled trial. Br J Dermatol. 2018;

:1288-96. doi:10.1111/bjd.16240.

Fuggle NR, Bragoli W, Mahto A, Glover M, Martinez AE,

Kinsler VA. The adverse effect profile of oral azathioprine

in pediatric atopic dermatitis, and recommendations

for monitoring. J Am Acad Dermatol. 2015;72:108-14.

doi:10.1016/j.jaad.2014.08.048.

Orvis AK, Wesson SK, Breza TSJ, Church AA, Mitchell

CL, Watkins SW. Mycophenolate mofetil in dermatology.

J Am Acad Dermatol. 2009;60:182-3. doi:10.1016/j.

jaad.2008.08.049.

Salvadori M, Bertoni E, Budde K, Holzer H, Civati

G, Lien B, et al. Superior efficacy of enteric-coated

mycophenolate vs mycophenolate mofetil in de

novo transplant recipients: pooled analysis. Transplant

Proc. 2010;42:1325-8. doi:10.1016/j.transproceed.

03.044.

Murray ML, Cohen JB. Mycophenolate mofetil therapy

for moderate to severe atopic dermatitis. Clin

Exp Dermatol. 2007;32:23-7. doi:10.1111/j.1365-

2006.02290.x.

Garritsen FM, Roekevisch E, van der Schaft J, Deinum J,

Spuls PI, de Bruin-Weller MS. Ten years experience with

oral immunosuppressive treatment in adult patients with

atopic dermatitis in two academic centres. J Eur Acad

Dermatol Venereol. 2015;29:1905-12. doi:10.1111/

jdv.13064.

Bangert CA, Costner MI. Methotrexate in dermatology.

Dermatol Ther. 2007;20:216-28. doi:10.1111/j.1529-

2007.00135.x.

Dogra S, Mahajan R. Systemic methotrexate therapy for

psoriasis: past, present and future. Clin Exp Dermatol.

;38:573-88. doi:10.1111/ced.12062.

El-Khalawany MA, Hassan H, Shaaban D, Ghonaim N,

Eassa B. Methotrexate versus cyclosporine in the treatment

of severe atopic dermatitis in children: a multicenter

experience from Egypt. Eur J Pediatr. 2013;172:351-6.

doi:10.1007/s00431-012-1893-3.

Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ.

An open-label, dose-ranging study of methotrexate

for moderate-to-severe adult atopic eczema. Br J

Dermatol. 2007;156:346-51. doi:10.1111/j.1365-

2006.07686.x.

Lyakhovitsky A, Barzilai A, Heyman R, Baum S, Amichai

B, Solomon M, et al. Low-dose methotrexate treatment

for moderate-to-severe atopic dermatitis in adults. J Eur

Acad Dermatol Venereol. 2010;24:43-9. doi:10.1111/

j.1468-3083.2009.03351.x.

Goujon C, Berard F, Dahel K, Guillot I, Hennino A, Nosbaum

A, et al. Methotrexate for the treatment of adult

atopic dermatitis. Eur J Dermatol. 2006;16:155-8.

Heddle RJ, Soothill JF, Bulpitt CJ, Atherton DJ. Combined

oral and nasal beclomethasone diproprionate in children

with atopic eczema: a randomised controlled trial.

Br Med J. 1984;289:651-4.

Galli E, Chini L, Moschese V, Paone F, Menichelli A, Fraioli

G, et al. Methylprednisolone bolus: a novel therapy for

severe atopic dermatitis. Acta Paediatr. 1994;83:315-7.

Schmitt J, Schakel K, Folster-Holst R, Bauer A, Oertel

R, Augustin M, et al. Prednisolone vs. ciclosporin

for severe adult eczema. An investigator-initiated

double-blind placebo-controlled multicentre trial. Br

J Dermatol. 2010;162:661-8. doi:10.1111/j.1365-

2009.09561.x.

Schadt CR, Jackson SM. Glucocorticoids. In: Bolognia

JL, Schaffer J V, Cerroni L, editors. Dermatology. 4th Ed.

Amsterdam: Elsevier; 2018:2186-99.

Akdis CA, Akdis M, Bieber T, Boguniewicz M, Eigenmann

P, Hamid Q, et al. Diagnosis and treatment of

atopic dermatitis in children and adults: European Academy

of Allergology and Clinical Immunology/American

Academy of Allergy, Asthma and Immunology/

PRACTALL Consensus Report. Allergy. 2006;61:969-87.

doi:10.1111/j.1398-9995.2006.01153.x.

Drucker AM, Eyerich K, de Bruin-Weller MS, Thyssen JP,

Spuls PI, Irvine AD, et al. Use of systemic corticosteroids

for atopic dermatitis: International Eczema Council

consensus statement. Br J Dermatol. 2018;178:768-75.

doi:10.1111/bjd.15928.

Hanifin JM, Chan SC. Monocyte phosphodiesterase

abnormalities and dysregulation of lymphocyte function

in atopic dermatitis. J Invest Dermatol. 1995;105(1

Suppl):84S-88S.

Samrao A, Berry TM, Goreshi R, Simpson EL. A

pilot study of an oral phosphodiesterase inhibitor

(apremilast) for atopic dermatitis in adults. Arch

Dermatol. 2012;148:890-7. doi:10.1001/archdermatol.

812.

Volf EM, Au SC, Dumont N, Scheinman P, Gottlieb AB. A

phase 2, open-label, investigator-initiated study to evaluate

the safety and efficacy of apremilast in subjects

with recalcitrant allergic contact or atopic dermatitis. J

Drugs Dermatol. 2012;11:341-6.

Abrouk M, Farahnik B, Zhu TH, Nakamura M, Singh

R, Lee K, et al. Apremilast treatment of atopic dermatitis

and other chronic eczematous dermatoses. J Am

Acad Dermatol. 2017;77:177-80. doi:10.1016/j.

jaad.2017.03.020.

Saporito RC, Cohen DJ. Apremilast use for moderate-to-

-severe atopic dermatitis in pediatric patients. Case Rep

Dermatol. 2016;8:179-84. doi:10.1159/000446836.

Farahnik B, Beroukhim K, Nakamura M, Abrouk M, Zhu

TH, Singh R, et al. Use of an oral phosphodiesterase-4

inhibitor (apremilast) for the treatment of chronic, severe

atopic dermatitis: a case report. Dermatol Online J.

;23.

Simon D, Hosli S, Kostylina G, Yawalkar N, Simon

HU. Anti-CD20 (rituximab) treatment improves atopic

eczema. J Allergy Clin Immunol. 2008;121:122-8.

doi:10.1016/j.jaci.2007.11.016.

Ponte P, Lopes MJ. Apparent safe use of single dose rituximab

for recalcitrant atopic dermatitis in the first

trimester of a twin pregnancy. J Am Acad Dermatol.

;63:355-6. doi:10.1016/j.jaad.2009.05.015.

Sedivá A, Kayserová J, Vernerová E, Poloucková A, Capková

S, Spísek R, et al. Anti-CD20 (rituximab) treatment

for atopic eczema. J Allergy Clin Immunol.

;121:1515-7. doi:10.1016/j.jaci.2008.03.007.

McDonald BS, Jones J, Rustin M. Rituximab as a treatment

for severe atopic eczema: failure to improve in three

consecutive patients. Clin Exp Dermatol. 2016;41:45-7.

doi:10.1111/ced.12691.

Simon D, Wittwer J, Kostylina G, Buettiker U, Simon HU,

Yawalkar N. Alefacept (lymphocyte function-associated

molecule 3/IgG fusion protein) treatment for atopic

eczema. J Allergy Clin Immunol. 2008;122:423-4.

doi:10.1016/j.jaci.2008.06.010.

Moul DK, Routhouska SB, Robinson MR, Korman NJ. Alefacept

for moderate to severe atopic dermatitis: a pilot

study in adults. J Am Acad Dermatol. 2008;58:984-9.

doi:10.1016/j.jaad.2008.02.007.

Jacobi A, Antoni C, Manger B, Schuler G, Hertl M. Infliximab

in the treatment of moderate to severe atopic

dermatitis. J Am Acad Dermatol. 2005;52:522-6.

doi:10.1016/j.jaad.2004.11.022.

Vestergaard C, Deleuran M, Kragballe K. Two cases

of atopic dermatitis-like conditions induced in psoriasis

patients treated with infliximab. J Eur Acad

Dermatol Venereol. 2007;21:1272-4. doi:10.1111/

j.1468-3083.2007.02165.x.

Ruiz-Villaverde R, Galan-Gutierrez M. Exacerbation of

atopic dermatitis in a patient treated with infliximab.

Actas Dermosifiliogr. 2012;103:743-6. doi:10.1016/j.

ad.2011.11.013.

Wright RC. Atopic dermatitis-like eruption precipitated

by infliximab. J Am Acad Dermatol. 2003;49:160-1.

doi:10.1067/mjd.2003.252.

Fernandez-Anton Martinez MC, Leis-Dosil V, Alfageme-

Roldan F, Paravisini A, Sanchez-Ramon S, Suarez

Fernandez R. Omalizumab for the treatment of atopic

dermatitis. Actas Dermosifiliogr. 2012;103:624-8.

doi:10.1016/j.ad.2011.07.013.

Forman SB, Garrett AB. Success of omalizumab as monotherapy

in adult atopic dermatitis: case report and

discussion of the high-affinity immunoglobulin E receptor,

FcepsilonRI. Cutis. 2007;80:38-40.

Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J,

Hussain I. Efficacy of anti-IgE therapy in patients with

atopic dermatitis. J Am Acad Dermatol. 2006;55:168-

doi:10.1016/j.jaad.2005.12.045.

Garmhausen D, Hagemann T, Bieber T, Dimitriou I,

Fimmers R, Diepgen T,et al. Characterization of different

courses of atopic dermatitis in adolescent and adult

patients. Allergy. 2013;68:498-506. doi:10.1111/

all.12112.

Kim DH, Park KY, Kim BJ, Kim MN, Mun SK. Anti-

-immunoglobulin E in the treatment of refractory atopic

dermatitis. Clin Exp Dermatol. 2013;38:496-500.

doi:10.1111/j.1365-2230.2012.04438.x.

Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger

S, et al. Low-dose anti-IgE therapy in patients

with atopic eczema with high serum IgE levels. J Allergy

Clin Immunol. 2007;120:1223-5. doi:10.1016/j.

jaci.2007.08.060.

Hotze M, Baurecht H, Rodriguez E, Chapman-Rothe

N, Ollert M, Fölster-Holst R, et al. Increased efficacy of

omalizumab in atopic dermatitis patients with wild-type

filaggrin status and higher serum levels of phosphatidylcholines.

Allergy. 2014;69:132-5. doi:10.1111/

all.12234.

Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer

WB. Efficacy of omalizumab in the treatment of atopic

dermatitis: a pilot study. Allergy asthma Proc.

;29:530-7. doi:10.2500/aap.2008.29.3160.

Velling P, Skowasch D, Pabst S, Jansen E, Tuleta I, Grohe

C. Improvement of quality of life in patients with concomitant

allergic asthma and atopic dermatitis: one

year follow-up of omalizumab therapy. Eur J Med Res.

;16:407-10.

Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab

therapy in atopic dermatitis: depletion of IgE

does not improve the clinical course - a randomized,

placebo-controlled and double blind pilot study. J Dtsch

Dermatol Ges. 2010;8:990-8. doi:10.1111/j.1610-

2010.07497.x.

Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui

J,et al. Anti-IL-5 recombinant humanized monoclonal

antibody (mepolizumab) for the treatment of atopic dermatitis.

Allergy. 2005;60:693-6. doi:10.1111/j.1398-

2005.00791.x.

Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting

pathogenesis of atopic dermatitis and psoriasis--part I:

clinical and pathologic concepts. J Allergy Clin Immunol.

;127:1110-8. doi:10.1016/j.jaci.2011.01.053.

Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol

Rev. 2011;242:233-246. doi:10.1111/j.1600-

X.2011.01027.x.

Borges AS, Pinheiro R, Brasileiro A. Dermite atópica : os

novos conhecimentos sobre a fisiopatologia da doença.

Rev Soc Port Dermatol Venereol. 2017;75:117-122.

Shirley M. Dupilumab: First Global Approval. Drugs.

;77:1115-21. doi:10.1007/s40265-017-0768-3.

Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber

T, Rocklin R, et al. Dupilumab treatment in adults with

moderate-to-severe atopic dermatitis. N Engl J Med.

;371:130-9. doi:10.1056/NEJMoa1314768.

Simpson EL, Gadkari A, Worm M, Soong W, Blauvelt

A, Eckert L, et al. Dupilumab therapy provides clinically

meaningful improvement in patient-reported outcomes

(PROs): A phase IIb, randomized, placebo-controlled,

clinical trial in adult patients with moderate to severe atopic

dermatitis (AD). J Am Acad Dermatol. 2016;75:506-

doi:10.1016/j.jaad.2016.04.054.

Hamilton JD, Suarez-Farinas M, Dhingra N, Cardinale I,

Li X, Kostic A, et al. Dupilumab improves the molecular

signature in skin of patients with moderate-to-severe atopic

dermatitis. J Allergy Clin Immunol. 2014;134:1293-

doi:10.1016/j.jaci.2014.10.013.

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt

A, Cork MJ,et al. Two phase 3 trials of dupilumab

versus placebo in atopic dermatitis. N Engl J Med.

;375:2335-48. doi:10.1056/NEJMoa1610020.

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather

JC, Weisman J, Pariser D, et al. Long-term management

of moderate-to-severe atopic dermatitis with dupilumab

and concomitant topical corticosteroids (LIBERTY AD

CHRONOS): a 1-year, randomised, double-blinded, placebo-

controlled, phase 3 trial. Lancet. 2017;389:2287-

doi:10.1016/S0140-6736(17)31191-1.

Sanofi, Regeneron Pharmaceuticals. Study to Assess the

Long-term Safety of Dupilumab Administered in Participants

≥6 Months to <18 Years of Age With Atopic

Dermatitis (AD). NCT02612454 @ clinicaltrials.gov.

[Accessed September 26, 2018]Available from:https://

clinicaltrials.gov/ct2/show/NCT02612454. 2018.

Sanofi, Regeneron Pharmaceuticals. Efficacy and Safety

of Dupilumab in Patients ≥12 to <18 Years of Age, With

Moderate-to-Severe Atopic Dermatitis. NCT03054428

@ clinicaltrials.gov. [Accessed September 26, 2018]

Available from:https://clinicaltrials.gov/ct2/show/record/

NCT03054428. 2018.

Sanofi, Regeneron Pharmaceuticals. Study to Investigate

the Efficacy and Safety of Dupilumab Administered

With Topical Corticosteroids (TCS) in Participants

≥6 to <12 Years With Severe Atopic Dermatitis (AD).

NCT03345914 @ clinicaltrials.gov. [Accessed September

, 2018]Available from:https://clinicaltrials.gov/

ct2/show/record/NCT03345914. 2018.

Sanofi, Regeneron Pharmaceuticals. Safety, Pharmacokinetics

and Efficacy of Dupilumab in Patients ≥6 Months

to <6 Years With Severe Atopic Dermatitis (Liberty AD

PRESCHOOL). NCT03346434 @ clinicaltrials.gov. [Accessed

September 26, 2018]Available from:https://clinicaltrials.

gov/ct2/show/NCT03346434. 2018.

Simpson E. Dupilumab Efficacy and Safety in Adolescents

with Moderate-to-Severe Atopic Dermatitis: Results

from a Multicenter, Randomized, Placebo-Controlled,

Double-Blind, Parallel-Group, Phase 3 Study. In: 27th

European Academy of Dermatology and Venereology

(EADV) Congress. Paris; 2018:Abstract D3T01.1L. Presented

September 15, 2018.

Jolles S. A review of high-dose intravenous immunoglobulin

treatment for atopic dermatitis. Clin Exp Dermatol.

;27:3-7.

Bemanian MH, Movahedi M, Farhoudi A, Gharagozlou

M, Seraj MH, Pourpak Z,et al. High doses intravenous

immunoglobulin versus oral cyclosporine in the treatment

of severe atopic dermatitis. Iran J Allergy Asthma

Immunol. 2005;4:139-43. doi:04.03/ijaai.139143.

Gorgun G, Miller KB, Foss FM. Immunologic mechanisms

of extracorporeal photochemotherapy in chronic

graft-versus-host disease. Blood. 2002;100:941-7.

doi:10.1182/blood-2002-01-0068.

Chiricozzi A, Faleri S, Lanti A, Adorno G, Lorè B, Chimenti

S, et al. Apheresis in the treatment of recalcitrant

atopic dermatitis: case series and review of the literature.

Eur J Dermatol. 2014;24:545-50. doi:10.1684/

ejd.2014.2383.

Radenhausen M, Michelsen S, Plewig G, Bechara

FG, Altmeyer P, Hoffmann K. Bicentre experience in

the treatment of severe generalised atopic dermatitis

with extracorporeal photochemotherapy. J Dermatol.

;31:961-70.

Koppelhus U, Poulsen J, Grunnet N, Deleuran MS, Obitz

E. Cyclosporine and extracorporeal photopheresis are

equipotent in treating severe atopic dermatitis: a randomized

cross-over study comparing two efficient treatment

modalities. Front Med. 2014;1:33. doi:10.3389/

fmed.2014.00033.

Akdis CA. Therapies for allergic inflammation: refining

strategies to induce tolerance. Nat Med. 2012;18:736-

doi:10.1038/nm.2754.

Compalati E, Rogkakou A, Passalacqua G, Canonica

GW. Evidences of efficacy of allergen immunotherapy

in atopic dermatitis: an updated review. Curr Opin Allergy

Clin Immunol. 2012;12:427-33. doi:10.1097/

ACI.0b013e328354e540.

Darsow U, Forer I, Ring J. Allergen-specific immunotherapy

in atopic eczema. Curr Allergy Asthma Rep.

;11:277-83. doi:10.1007/s11882-011-0194-7.

Tam H, Calderon MA, Manikam L, Nankervis H, García

Núñez I, Williams HC, et al. Specific allergen immunotherapy

for the treatment of atopic eczema.

Cochrane Database Syst Rev. 2016;2:CD008774.

doi:10.1002/14651858.CD008774.pub2.

Wegner J, Weinmann-Menke J, von Stebut E. Immunoadsorption for treatment of severe atopic dermatitis.

Atheroscler Suppl. 2017; 30:264-70. doi:10.1016/j.

atherosclerosissup.2017.05.043.

Cotter DG, Schairer D, Eichenfield L. Emerging therapies

for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol.

;78:S53-S62. doi:10.1016/j.jaad.2017.12.019.

Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB,

Wilke A, Prescilla R, et al. Baricitinib in adult patients

with moderate-to-severe atopic dermatitis: a phase 2

parallel, double-blinded, randomized placebo-controlled

multiple-dose study. J Am Acad Dermatol. 2018.

doi:10.1016/j.jaad.2018.01.018.

Fraser KA. American Academy of Dermatology Annual

Meeting: San Diego, CA, USA, 16-20 Feb 2018. Am J

Clin Dermatol. 2018;19:287-90. doi:10.1007/s40257-

-0351-z.

Damsky W, King BA. JAK inhibitors in dermatology:

The promise of a new drug class. J Am Acad Dermatol.

;76:736-44. doi:10.1016/j.jaad.2016.12.005.

Levy LL, Urban J, King BA. Treatment of recalcitrant atopic

dermatitis with the oral Janus kinase inhibitor tofacitinib

citrate. J Am Acad Dermatol. 2015;73:395-9.

doi:10.1016/j.jaad.2015.06.045.

Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman

M, Mallbris L, et al. Topical tofacitinib for atopic dermatitis:

a phase IIa randomized trial. Br J Dermatol.

;175:902-911. doi:10.1111/bjd.14871.

Kim BE, Leung DYM, Boguniewicz M, Howell MD. Loricrin

and involucrin expression is down-regulated by Th2

cytokines through STAT-6. Clin Immunol. 2008;126:332-

doi:10.1016/j.clim.2007.11.006.

Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen

H, Taïeb A, et al. Efficacy and safety of lebrikizumab

(an anti-IL-13 monoclonal antibody) in adults with

moderate-to-severe atopic dermatitis inadequately

controlled by topical corticosteroids: A randomized,

placebo-controlled phase II trial (TREBLE). J Am Acad

Dermatol. 2018;78:863-871.e11. doi:10.1016/j.

jaad.2018.01.017.

Andreas Wollenberg, Michael D. Howell, Emma Guttman-

Yassky, Jonathan I. Silverberg, Claire Birrell, Chris

Kell, Michelle Dawson R van der M. A phase 2b dose-

-ranging efficacy and safety study of tralokinumab

in adult patients with moderate to severe atopic dermatitis

(AD). J Am Acad Dermatol. 2017;76(6):AB20.

doi:10.1016/j.jaad.2017.04.099.

Nemoto O, Furue M, Nakagawa H, Shiramoto M, Hanada

R, Matsuki S, et al. The first trial of CIM331, a humanized

antihuman interleukin-31 receptor A antibody,

in healthy volunteers and patients with atopic dermatitis

to evaluate safety, tolerability and pharmacokinetics of

a single dose in a randomized, double-blind, placebo-

-co. Br J Dermatol. 2016;174:296-304. doi:10.1111/

bjd.14207.

Cornelissen C, Marquardt Y, Czaja K, Wenzel J, Frank

J, Lüscher-Firzlaff J, et al. IL-31 regulates differentiation

and filaggrin expression in human organotypic skin models.

J Allergy Clin Immunol. 2012;129:426-33, 433-8.

doi:10.1016/j.jaci.2011.10.042.

Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I,

Wollenberg A, et al. Anti-Interleukin-31 receptor A antibody

for atopic dermatitis. N Engl J Med. 2017;376:826-

doi:10.1056/NEJMoa1606490.

Kabashima K, Furue M, Hanifin JM, Pulka G, Wollenberg

A, Galus R, et al. Nemolizumab in patients with

moderate-to-severe atopic dermatitis: Randomized,

phase II, long-term extension study. J Allergy Clin Immunol.

(in press). doi:10.1016/j.jaci.2018.03.018.

Novartis, Icahn School of Medicine at Mount Sinai.

Secukinumab for Treatment of Atopic Dermatitis.

NCT02594098 @ clinicaltrials.gov. [Accessed September

, 2018]Available from:https://clinicaltrials.gov/

ct2/show/NCT02594098. P2018.

Novartis, GWT-TUD GmbH. Investigation of Efficacy of Secukinumab

in Patients With Moderate to Serve Atopic Dermatitis

(Secu_in_AD). NCT03568136 @ clinicaltrials.gov.

[Accessed September 26, 2018]Available from:https://

clinicaltrials.gov/ct2/show/NCT03568136. 2018.




DOI: http://dx.doi.org/10.29021/spdv.76.4.958

Apontadores

  • Não há apontadores.




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.